Keyword: Sage Therapeutics
An FDA advisory committee voted 17-1 on Friday to recommend the approval of Sage Therapeutics’ postpartum depression drug, brexanolone.
There’s no one-size-fits-all solution when it comes to academic partnerships, but successful ones have one thing in common: communication.
Martin Shkreli, infamous for his combative tweets and general "insolent" demeanor, may be blogging biopharma tips from prison.
Securing the status positions Sage to receive a decision from the FDA by the end of the year.
In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.
SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.
The trials linked the drug to improvements on a depression scale, teeing Sage up to file for approval next year and sending its stock up 44%.
Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”
Sage Therapeutics has posted a late-stage failure for brexanolone.
Sage Therapeutics posted phase 2 results from its Parkinson’s disease study yesterday in which it said its experimental med could help tremors, but the top-line data were met with confusion by Bio Twitter, and its shares fell more than 3% in normal hours trading.